Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Did PTSC buyback shares during the so called "black out"?

Did PTSC buyback shares during the so called "black out"?

posted on Apr 10, 2008 08:21AM

Patriot Scientific's Disappointing Results for Three/Nine Months Ended 2/29/08 Raise More Questions than Answers;

Speculative Buy Reiterated; Reducing Price Target to $0.55 Per Share

Patriot Scientific Corporation (Patriot Scientific) results for the three months and nine months ended February 29, 2008.

In the nine months ended February 29, 2008, Patriot Scientific received cash distributions from Phoenix Digital totaling $16.7 million and

cash distributions from Phoenix Digital in the three months ended February 29, 2008, were $9.0 million.

In the three months ended February 29, 2008, Phoenix Digital's (the partnership) revenue from technology license

agreements was

approximately $27.9 million and in the nine months ended February 29, 2008, Phoenix Digital's revenue from technology license

agreements was approximately $48.9 million. After operating expenses of

approximately $16.0 million and interest income of $177,281,

Phoenix Digital's net income in the nine months ended February 29, 2008, that is

divided 50/50 between TPL and Patriot Scientific, was

approximately $32.7 million and Patriot Scientific's share for the three-month period was approximately $11.7 million.

The major unanswered question is whether or not the gross revenue of $27.9 million received by Phoenix

Digital for the three months

ended February 29, 2008, includes the December settlement for the granting by TPL of rights under the Moore

Microprocessor Patent

Portfolio to NEC Electronics America, Toshiba, Matsushita, and JVC and their respective subsidiaries in the form of license agreements.

If in fact the $27.9 million does include this January settlement, it appears that the licenses granted in the three months

averaged out to

be $ 1.8 million per license.

Patriot Scientific's balance sheet as of February 29, 2008, shows cash and short-term

investments totaling $23.2 million, compared with

$26.0 million as of February 28, 2008. As of February 29, 2008, current assets were $25.6

million and current liabilities were $4.6

million, including $4.0 million income tax payable. Patriot Scientific utilized cash of $5.8 million to

buy back, 5,698,821 shares of its

common stock at an average price of $0.534 per share.

SUMMARY

We, as well as many investors, were anxiously awaiting the release of the results for the three months

ended 2/29/2008, and the low

dollar volume of license revenue falls way short of investors' and our expectations. This short-fall was reflected in

Patriot Scientific's

stock price, today April 10, 2008, that opened at $0.42 and by 10:00 AM EST, and quickly traded down into the mid $0.30's on

heavy

volume. Considering there were either 12 licenses granted (or 15, if

the December settlements from the trial were included), this net

income works out to be approximately $450,000 to $550,000 per license granted.

In addition, the release graphically illustrates the status of Patriot Scientific. As a passive partner in the joint venture

with Technology

Properties Limited (TPL), Patriot Scientific is entirely dependent on the success or failure of the licensing and prosecution efforts of TPL

on behalf of the joint venture. Further, Patriot Scientific has no control over the amount per license being granted by TPL or Phoenix

Digital's operating expenses. This situation points up the need for Patriot Scientific to utilize its cash for acquisition of revenue and

earnings producing companies. Finally, the lack of transparency that has

evolved with the TPL partnership creates a situation where

investors are forced to estimate the dollar value of licenses granted, even after SEC filings.

Share
New Message
Please login to post a reply